{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:51:50Z","timestamp":1769115110336,"version":"3.49.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["AZV 17-28784A"],"award-info":[{"award-number":["AZV 17-28784A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU20-02-00052"],"award-info":[{"award-number":["NU20-02-00052"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NV19-02-00130"],"award-info":[{"award-number":["NV19-02-00130"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU21-02-00402"],"award-info":[{"award-number":["NU21-02-00402"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Phosphodiesterase-5a inhibition (PDE5i) leads to favorable changes in pulmonary hemodynamic and cardiac output (CO) in patients with advanced heart failure (HF) and reduced ejection fraction (HFrEF). The hemodynamic response to PDE5i could be heterogeneous and the clinical variables associated with these changes are scarcely investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Of 260 patients with advanced HFrEF referred for advanced therapies [cardiac transplant\/left ventricular assist device (LVAD)], 55 had pulmonary hypertension (PH) and fulfilled the criteria for the PDE5i vasoreactivity test. Right heart catheterization (RHC) was performed as a part of clinical evaluation before and after 20-mg intravenous sildenafil. Absolute and relative changes in pulmonary vascular resistance (PVR) were evaluated to assess hemodynamic response to PDE5i. Clinical, biochemical, and hemodynamic factors associated with PVR changes were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sildenafil administration reduced PVR (\u2212 45.3%) and transpulmonary gradient (TPG; \u2212 34.8%) and increased CO (+ 13.6%). Relative change analysis showed a negative moderate association between baseline plasma potassium and changes in PVR (<jats:italic>r<\/jats:italic> = \u2212 0.48; <jats:italic>p<\/jats:italic> = 0.001) and TPG (<jats:italic>r<\/jats:italic> = \u2212 0.43; <jats:italic>p<\/jats:italic> = 0.005) after PDE5i. Aldosterone concentration shows a direct moderate association with PVR changes after PDE5i. A significant moderate association was also demonstrated between CO improvement and the severity of mitral (<jats:italic>r<\/jats:italic> = 0.42; <jats:italic>p<\/jats:italic> = 0.002) and tricuspid (<jats:italic>r<\/jats:italic> = 0.39; <jats:italic>p<\/jats:italic> = 0.004) regurgitation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We identified plasma potassium, plasma aldosterone level, and atrioventricular valve regurgitations as potential cofounders of hemodynamic response to acute administration of PDE5i. Whether modulation of potassium levels could enhance pulmonary vasoreactivity in advanced HFrEF deserves further research.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.883911","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:47:55Z","timestamp":1654253275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Pulmonary Vasculature Responsiveness to Phosphodiesterase-5A Inhibition in Heart Failure With Reduced Ejection Fraction: Possible Role of Plasma Potassium"],"prefix":"10.3389","volume":"9","author":[{"given":"Luca","family":"Monzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Reichenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikmet","family":"Al-Hiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Jurcova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Huskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Kautzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vojtech","family":"Melenovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jchf.2013.05.001","article-title":"Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure.","volume":"1","author":"Miller","year":"2013","journal-title":"JACC Heart Fail."},{"key":"B2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s0735-1097(00)01102-5","article-title":"Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure.","volume":"37","author":"Ghio","year":"2001","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1161\/CIRCULATIONAHA.106.626226","article-title":"Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.","volume":"115","author":"Lewis","year":"2007","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease.","volume":"53","author":"Vachiery","year":"2019","journal-title":"Eur Respir J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/s1053-2498(01)00286-8","article-title":"Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation.","volume":"20","author":"Delgado","year":"2001","journal-title":"J Heart Lung Transplant."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006252","article-title":"Long-term survival of patients with advanced heart failure receiving an left ventricular assist device intended as a bridge to transplantation: the registry to evaluate the heartware left ventricular assist system.","volume":"13","author":"Zimpfer","year":"2020","journal-title":"Circ Heart Fail."},{"key":"B7","first-page":"S52","article-title":"Right heart failure post left ventricular assist device implantation.","volume":"6","author":"Argiriou","year":"2014","journal-title":"J Thorac Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.jtcvs.2009.11.020","article-title":"Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes.","volume":"139","author":"Kormos","year":"2010","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/0735-1097(92)90050-w","article-title":"Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group.","volume":"19","author":"Costard-Jackle","year":"1992","journal-title":"J Am Coll Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.amjcard.2009.11.026","article-title":"Risk factors predictive of right ventricular failure after left ventricular assist device implantation.","volume":"105","author":"Drakos","year":"2010","journal-title":"Am J Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jacc.2009.05.021","article-title":"Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil.","volume":"54","author":"Melenovsky","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijcard.2012.09.074","article-title":"The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control study.","volume":"168","author":"Reichenbach","year":"2013","journal-title":"Int J Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1161\/CIRCHEARTFAILURE.108.796789","article-title":"PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.","volume":"1","author":"Tedford","year":"2008","journal-title":"Circ Heart Fail."},{"key":"B14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/MAT.0000000000000626","article-title":"Sildenafil in left ventricular assist device is safe and well-tolerated.","volume":"64","author":"Ravichandran","year":"2018","journal-title":"ASAIO J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cardfail.2020.11.007","article-title":"Acute unloading effects of sildenafil enhance right ventricular-pulmonary artery coupling in heart failure.","volume":"27","author":"Monzo","year":"2021","journal-title":"J Card Fail."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004255","article-title":"Intersection of Pulmonary hypertension and right ventricular dysfunction in patients on left ventricular assist device support: is there a role for pulmonary vasodilators?","volume":"11","author":"Sparrow","year":"2018","journal-title":"Circ Heart Fail."},{"key":"B17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cardfail.2020.12.018","article-title":"Phosphodiesterase-5 inhibitors and outcomes during left ventricular assist device support: a systematic review and meta-analysis.","volume":"27","author":"Kittipibul","year":"2021","journal-title":"J Card Fail."},{"key":"B18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.33549\/physiolres.931951","article-title":"Sildenafil is more selective pulmonary vasodilator than prostaglandin E1 in patients with pulmonary hypertension due to heart failure.","volume":"60","author":"Al-Hiti","year":"2011","journal-title":"Physiol Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.healun.2009.04.013","article-title":"Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.","volume":"28","author":"Botha","year":"2009","journal-title":"J Heart Lung Transplant."},{"key":"B20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/2045893217697708","article-title":"Identifying \u201csuper responders\u201d in pulmonary arterial hypertension.","volume":"7","author":"Halliday","year":"2017","journal-title":"Pulm Circ."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA."},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005537","article-title":"Preimplant phosphodiesterase-5 inhibitor use is associated with higher rates of severe early right heart failure after left ventricular assist device implantation.","volume":"12","author":"Gulati","year":"2019","journal-title":"Circ Heart Fail."},{"key":"B23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging.","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ehjci\/jet105","article-title":"Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European association of cardiovascular imaging.","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.jacc.2013.06.046","article-title":"Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.","volume":"62","author":"Melenovsky","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1164\/rccm.201402-0269PP","article-title":"Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings.","volume":"190","author":"Kovacs","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension.","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11897-004-0007-6","article-title":"Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.","volume":"1","author":"Lewis","year":"2004","journal-title":"Curr Heart Fail Rep."},{"key":"B29","first-page":"I70","article-title":"Electrolyte abnormalities underlying lethal and ventricular arrhythmias.","volume":"85","author":"Gettes","year":"1992","journal-title":"Circulation."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1161\/circulationaha.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality.","volume":"137","author":"Nunez","year":"2018","journal-title":"Circulation."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1183\/13993003.00798-2015","article-title":"Potassium channels in pulmonary arterial hypertension.","volume":"46","author":"Boucherat","year":"2015","journal-title":"Eur Respir J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1161\/HYPERTENSIONAHA.119.12992","article-title":"Pulmonary hypertension and ATP-sensitive potassium channels.","volume":"74","author":"McClenaghan","year":"2019","journal-title":"Hypertension."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/biom10091261","article-title":"Implication of potassium channels in the pathophysiology of pulmonary arterial hypertension.","volume":"10","author":"Le Ribeuz","year":"2020","journal-title":"Biomolecules."},{"key":"B34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/eurjhf\/hfs173","article-title":"Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study.","volume":"15","author":"Maron","year":"2013","journal-title":"Eur J Heart Fail."},{"key":"B35","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation."},{"key":"B36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s0008-6363(00)00223-6","article-title":"Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates.","volume":"49","author":"Huang","year":"2001","journal-title":"Cardiovasc Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.jacc.2009.04.008","article-title":"Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension.","volume":"54","author":"Hoeper","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jchf.2019.03.021","article-title":"The role of the pericardium in heart failure: implications for pathophysiology and treatment.","volume":"7","author":"Borlaug","year":"2019","journal-title":"JACC Heart Fail."},{"key":"B39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-2007-1022972","article-title":"Hemodynamic changes following experimental production and correction of acute mitral regurgitation with an adjustable ring prosthesis.","volume":"36","author":"Ahmadi","year":"1988","journal-title":"Thorac Cardiovasc Surg."},{"key":"B40","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/0002-9149(79)90077-8","article-title":"Mechanism of reduction of mitral regurgitation with vasodilator therapy.","volume":"43","author":"Yoran","year":"1979","journal-title":"Am J Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.","volume":"172","author":"Wharton","year":"2005","journal-title":"Am J Respir Crit Care Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"L678","DOI":"10.1152\/ajplung.00300.2012","article-title":"Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.","volume":"304","author":"Preston","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-018-0604-x","article-title":"Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.","volume":"18","author":"Boehm","year":"2018","journal-title":"BMC Pulm Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.883911\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:48:00Z","timestamp":1654253280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.883911\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":43,"alternative-id":["10.3389\/fcvm.2022.883911"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.883911","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"883911"}}